Kiniksa Pharmaceuticals International (KNSA) Depreciation and Depletion (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Depreciation and Depletion for 10 years, with the latest figure at $144000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion rose 311.43% year-over-year to $144000.0; the trailing twelve-month figure through Mar 2026 stood at $305000.0 (down 7.29% YoY), and the FY2025 full-year result was $196000.0, down 56.25% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $144000.0, up from $121000.0 in the prior quarter.
• The five-year high for Depreciation and Depletion was $359000.0 in Q1 2022, with the low at $13000.0 in Q2 2025.
• Historically, Depreciation and Depletion has averaged $181000.0 across 5 years, with a median of $154000.0 in 2024.
• Annual changes were most pronounced in 2025 — Depreciation and Depletion slumped 89.08% — and 2026, when it soared 311.43%.
• Kiniksa Pharmaceuticals International's Depreciation and Depletion stood at $294000.0 in 2022, then dropped by 19.73% to $236000.0 in 2023, then tumbled by 62.71% to $88000.0 in 2024, then jumped by 37.5% to $121000.0 in 2025, then grew by 19.01% to $144000.0 in 2026.
• The last three Depreciation and Depletion figures came in at $144000.0 (Q1 2026), $121000.0 (Q4 2025), and $27000.0 (Q3 2025), per Business Quant data.